National and Kapodistrian University of Athens
Μη επεμβατικοί δείκτες κυτταρικής γήρανσης ως εργαλείο εκτίμησης του κινδύνου εμφάνισης ηπατοκυτταρικού καρκίνου σε ασθενείς με χρόνια ηπατίτιδα Β
Abstract
dc:descriptionBACKROUND: Hepatocellular carcinoma (HCC) is the most serious complication of chronic hepatitis B (CHB), which may still develop in chronic hepatitis B (CHB) patients even under effective long-term antiviral therapy. However, its pathogenesis in the setting of CHB with long-standing inhibition of viral replication has not been completely elucidated. Recently, the detection of circulating cell-free (cf) DNA and nucleosomes has found numerous applications in oncology. This study aimed to investigate whether species of circulating cell-free DNA (cfDNA) may be involved in the process of hepatocarcinogenesis in treated CHB patients, to examine the levels of serum cfDNA markers and nucleosomes in CHB patients with and without HCC and to assess their potential associations with HCC patients’ survival. MATERIALS AND METHODS: Serum samples were obtained from 37 HBeAg-negative CHB patients with subsequent HCC and 74 matched controls with CHB but without HCC development during the first 5 years of antiviral therapy. Moreover, serum samples were obtained from 19 patients with CHB and diagnosed HCC and 38 matched patients with CHB and no HCC during 5 years of antiviral therapy. HCC cases and controls in both settings were matched at a 1:2 ratio for age, sex and platelets. Determination of different circulating cfDNA species including total cfDNA quantity, levels of Alu repeat DNA and RNAse P coding DNA, copies of mitochondrial DNA, levels of 5-methyl-2'-deoxycytidine as indicator of DNA methylation and circulating nucleosomes was performed. RESULTS: Patients who developed HCC during follow up, compared to their matched controls, had higher median levels of Alu247 (123 vs 69 genomic equivalent [GE], P=0.042) and RNAse P coding DNA (68 vs 15 GE, P<0.001). In contrast, median cfDNA concentration, Alu115 levels, Alu247/Alu115 ratio as an index of DNA integrity and mitochondrial DNA copies did not differ significantly between the two previous groups. Receiver operating characteristic curve analysis showed that levels RNAse P coding DNA offered good prediction of subsequent HCC development (c-statistic: 0.80, P<0.001). CHB patients with diagnosed HCC, compared to their matched controls, had higher median Alu247 levels (64.2 vs 23.2 GE, P=0.004) and DNA integrity (1.0 vs 0.7, P<0.001) and a trend for higher median cfDNA concentration (36.0 vs 19.5 ng/mL, P=0.064). Raised DNA integrity (Alu247/Alu115 >1) was associated with increased risk of death during the first year after HCC diagnosis (P=0.016) CONCLUSION: In conclusion, serum levels of RNAse P coding DNA are increased years before HCC diagnosis and could be potentially helpful in the prediction of the HCC risk in treated HBeAg-negative CHB patients. Levels of Alu247 and DNA integrity of serum cfDNA are elevated in CHB patients with diagnosed HCC, whereas raised DNA integrity seems to be associated with worse one-year prognosis in this setting.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papatheodoridi, Maria-Alkistis
- Παπαθεοδωρίδη, Μαρία-Άλκηστις
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52690